Plaque Assay–Based Quantification of Viral Load in an Infected Mouse Tissue Sample
JoVE Encyclopedia of Experiments
Microbiology
0 views • 3:40 min • July 1st, 2026
Loading...
Overview
This article details a protocol for quantifying infectious SARS-CoV-2 viral loads in tissue samples from K18 hACE2 transgenic mice using a plaque assay. The method involves infecting epithelial cell monolayers with tissue homogenate supernatants, followed by immunostaining and plaque counting to determine viral titers.
Key Study Components
Area of Science
- Virology
- Infectious disease research
- Quantitative viral assays
Background
- Accurate quantification of infectious virus in tissues is essential for evaluating viral pathogenesis and therapeutic interventions.
- Plaque assays are a gold standard for measuring infectious virus particles.
- K18 hACE2 transgenic mice are a widely used model for SARS-CoV-2 infection studies.
- Immunostaining enhances plaque visualization and specificity.
Purpose of Study
- To provide a detailed protocol for quantifying SARS-CoV-2 infection in mouse tissues.
- To enable reproducible measurement of viral titers using plaque assays and immunostaining.
- To facilitate studies of viral pathogenesis and intervention efficacy in transgenic mouse models.
Methods Used
- Preparation of tissue homogenates from virus-infected mice.
- Tenfold serial dilution of supernatants and infection of Vero E6 cell monolayers.
- Incubation with agar-containing overlay to restrict viral spread and form plaques.
- Fixation, permeabilization, and blocking of cells.
- Immunostaining with primary and biotin-conjugated secondary antibodies targeting viral nucleocapsid protein.
- Visualization using avidin-biotin-peroxidase complex and chromogenic substrate (DAB).
- Plaque counting and calculation of viral titers as plaque forming units per milliliter.
Main Results
- Clear, countable plaques are formed in infected cell monolayers.
- Immunostaining with nucleocapsid-specific antibodies enhances plaque detection.
- Viral titers can be accurately quantified from tissue samples.
- The protocol is reproducible and suitable for high-containment laboratory settings.
Conclusions
- The described plaque assay protocol enables precise quantification of infectious SARS-CoV-2 in mouse tissues.
- Immunostaining increases specificity and clarity of plaque visualization.
- This method supports robust evaluation of viral infection and intervention studies in transgenic mouse models.
Frequently Asked Questions
What is the main purpose of the plaque assay described in this protocol?
The main purpose is to quantify infectious SARS-CoV-2 viral loads in tissue samples from infected mice by counting plaques formed on cell monolayers.
Why is an agar overlay used during the assay?
The agar overlay restricts viral spread, ensuring that each plaque arises from a single infectious particle, allowing accurate quantification.
How are plaques visualized and counted?
Plaques are visualized by immunostaining with antibodies against the viral nucleocapsid protein, followed by chromogenic detection, and then counted at different dilutions.
What cell line is used for the plaque assay?
Vero E6 cells are used as the monolayer for infection and plaque formation.
How is specificity for SARS-CoV-2 ensured in this assay?
Specificity is achieved by using a monoclonal antibody that cross-reacts with the SARS-CoV nucleocapsid protein during immunostaining.
What biosafety precautions are necessary for this protocol?
The protocol requires biosafety level three (BSL-3) containment for handling infectious SARS-CoV-2 and inactivation steps before removing plates from containment.
How are viral titers calculated?
Viral titers are calculated as plaque forming units per milliliter (PFU/mL) based on the number of plaques at each dilution.
Executive Industry Relevance
Plaque assay–based quantification of viral load in infected mouse tissue provides a gold-standard, quantitative readout for infectious virus, supporting robust target validation and mechanistic de-risking in antiviral R&D. This method enables precise measurement of viral replication and intervention efficacy, informing early discovery and preclinical decision points. Its reproducibility and specificity are critical for portfolio triage and translational continuity in infectious disease pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative interrogation of antiviral hypotheses in disease-relevant mouse models.
- Supports functional validation of viral targets by measuring infectious output.
- Provides mechanistic de-risking by distinguishing infectious from non-infectious viral particles.
- Facilitates predictive confidence in target engagement and intervention effects.
Screening & Assay Development
- Delivers validated, quantitative viral load readouts for downstream screening workflows.
- Standardizes assay conditions for reproducibility and cross-study comparability.
- Enables scalability and platform reuse for compound evaluation in high-containment settings.
- Supports robust assay development with immunostaining-enhanced plaque detection.
Translational & Preclinical Research
- Aligns with disease-relevant in vivo models for translational biomarker development.
- Ensures continuity from discovery through preclinical validation of antiviral efficacy.
- Reduces risk in advancement decisions by providing quantitative infectious readouts.
- Supports mechanistic understanding of viral pathogenesis in model systems.
Pipeline & Workflow Integration
This plaque assay protocol integrates from early discovery through preclinical research, enabling hypothesis testing, screening, and translational validation in infectious disease pipelines.
- Discovery Biology: Quantifies infectious viral output to support hypothesis testing and biological de-risking.
- Screening: Provides reproducible, quantitative assay outputs for compound evaluation.
- Analytics: Enables statistical comparison of viral loads across experimental conditions and interventions.
- Translational Research: Bridges in vitro and in vivo findings for biomarker and efficacy alignment.
- Enterprise Reuse: Offers a standardized, reusable platform for infectious virus quantification across programs.
Operational & Enterprise Impact
- Scientific Value: Delivers predictive confidence and target validation through quantitative infectious readouts.
- Operational Value: Ensures assay standardization, reproducibility, and scalability in high-containment labs.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in antiviral portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of antiviral candidates.
Implementation Considerations
- Requires virology expertise and experience with high-containment (BSL-3) procedures.
- Needs access to specialized instrumentation for cell culture, immunostaining, and plaque visualization.
- Demands rigorous cross-team standardization for reproducibility and data comparability.
- May require adaptation for different viral strains or tissue types as supported by the protocol.
- Practical limitations include biosafety requirements and throughput constraints inherent to manual plaque counting.
Biopharma FAQs
Why does null hypothesis testing matter for plaque quantification?
Null hypothesis testing in plaque quantification enables objective assessment of whether observed differences in viral load between experimental groups are statistically significant, supporting robust target validation and mechanistic de-risking in antiviral discovery.
How does independent variable isolation fit the plaque assay workflow?
Isolating variables such as treatment conditions or genetic backgrounds in the plaque assay workflow ensures that changes in plaque counts directly reflect the effect of the intervention, increasing predictive confidence in early discovery and screening.
What do quantitative plaque counts enable in antiviral R&D?
Quantitative plaque counts provide precise measurement of infectious viral load, enabling comparison of intervention efficacy, dose-response relationships, and mechanistic insights across experimental arms in preclinical research.
Why are replication requirements critical for plaque assay studies?
Replication in plaque assay studies ensures reproducibility and reliability of viral load measurements, facilitating cross-functional collaboration and data integration across discovery and preclinical teams.
What statistical analysis capabilities are needed before plaque assay implementation?
Statistical analysis capabilities such as calculation of plaque forming units, assessment of variance, and significance testing are required to interpret quantitative outputs and support data-driven advancement decisions in antiviral pipelines.
04:41
Plaquing of Herpes Simplex Viruses
Related Videos
0 Views
04:06
Use of Crystal Violet to Improve Visual Cytopathic Effect-based Reading for Viral Titration using TCID50 Assays
Related Videos
0 Views
07:26
Virus Propagation and Cell-Based Colorimetric Quantification
Related Videos
0 Views
11:28
Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus
Related Videos
0 Views
13:22
Measurement of γHV68 Infection in Mice
Related Videos
0 Views
10:53
Plaque Assay for Murine Norovirus
Related Videos
0 Views
03:43
Virus Plaque Assay: A Technique to Measure Infectious Herpes Simplex Virus via Quantification of Plaques Formed in Monolayer of Virus-Infected Cells
Related Videos
0 Views
06:23
A Focus-Forming Assay for Quantifying Virus Titers in the Organs of an Infected Mouse
Related Videos
0 Views
02:48
Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
Related Videos
0 Views
09:28
Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems
Related Videos
0 Views
Last updated: 18 July 2026